Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

The highest TB rates in Kyrgyzstan are in Kara-Suu district, Osh province. Weekly meeting of the local medical staff with the supervising and counselling staff of MSF. Case review before medical round. Photograph by Helmut Wachter
Press release
Press release |
17 February 2015
Tuberculosis
Armenia

Tuberculosis: a joint MSF / Ministries of Health symposium to discuss new treatments and approaches in Eastern Europe and Central Asia

4 min
Press release |
26 January 2015
Vaccines

At Berlin Vaccine Summit, World leaders try their luck at spinning ‘Pharma’s Wheel of Fortune’

2013 marked the first time that PCV is being used in South Sudan and one of the first vaccines to be implemented in compliance with the new WHO emergency vaccination recommendations. Photograph by Yann Libessart
Press release
Press release |
26 January 2015
Vaccines

MSF responds to Pfizer announcement of pneumococcal vaccine price reduction

3 min
OCP MSF Hepatitis C clinic in Preah Kossamak Hospital, Phnom Penh, Cambodia Photograph by Dean Irvine
Press release
Press release |
26 January 2015
Hepatitis C Intellectual property and trade

MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence

3 min
Press release |
21 January 2015
Intellectual property and trade
India

Ahead of Obama visit, MSF warns US pressure on India could impact access to medicines for millions

DESCRIPTION:MSF stunt in Berlin outside the venue of the Gavi replenishment meeting, demanding GSK and Pfizer to reduce their price for the pneumococcal vaccine to $5 per child. The stunt involves world leaders spinning a wheel of chance in which - when it comes to the PCV vaccine - pharma almost always wins. Photograph by Stephanie Pilick
Press release
Press release |
20 January 2015
Vaccines

MSF response to GSK and Pfizer’s statement on the pneumonia vaccine (pneumococcal conjugate vaccine, PCV)

2 min
MSF held the first of three rounds of a mass vaccination campaign in Adjumani district of northern Uganda to protect children from deadly respiratory infections, July 2014. Photograph by Markel Redondo
Press release
Press release |
19 January 2015
Vaccines

MSF calls on GSK and Pfizer to slash pneumo vaccine price to $5 per child for poor countries ahead of donor meeting

5 min
DNP+ Protesting Photograph by Siddharth Singh
Press release
Press release |
14 January 2015
Hepatitis C Intellectual property and trade
India

Gilead denied patent for hepatitis C drug sofosbuvir in India

5 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury